Carina Biotech

Carina Biotech

Empowering patients to fight their cancer through next-generation CAR-T technologies.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
investor investor investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
*

$5.2m

Valuation: $27.0m

Early VC
Total Funding000k
Notes (0)
More about Carina Biotech
Made with AI
Edit

Carina Biotech is an Australian clinical-stage immunotherapy company focused on researching and developing chimeric antigen receptor T cell (CAR T) therapies to treat solid cancers. CAR T therapy is a groundbreaking treatment that harnesses a patient's immune system to combat cancer. Carina Biotech operates in the biotechnology and healthcare market, primarily serving patients with colorectal and ovarian cancers. The company collaborates with various industry participants, clinicians, healthcare providers, and research organizations to advance its CAR T programs. Carina Biotech generates revenue through partnerships, research grants, and potential future commercialization of its therapies. The company is actively involved in presenting its research findings at major industry conferences, attracting interest from pharmaceutical investors.

Keywords: CAR T therapy, immunotherapy, solid cancers, colorectal cancer, ovarian cancer, biotechnology, healthcare, clinical-stage, research, collaboration.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads